Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Summary
Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed/Refractory
Official title: Retrospective Observational Study in Patients With Relapsed / Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2022-04-23
Completion Date
2025-12
Last Updated
2025-01-30
Healthy Volunteers
No
Conditions
Locations (3)
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Bologna, Italy
Azienda Ospedaliera Universitaria- POLICLINICO BARI
Bari, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy